Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

The Phenylephrine Test Revisited

View through CrossRef
Purpose: To characterize the phenylephrine test in ptotic patients to help clinicians perform the test more efficiently. Methods: Adults with involutional ptosis (n = 24, 30 eyes) were assessed with digital photographs for response to topical 2.5% phenylephrine drop instillation. Patient characteristics (age, gender, iris color, dermatochalasis, brow ptosis, and baseline marginal reflex distance-1 [MRD-1] height) were recorded. From the photographs, change in (MRD-1), presence of conjunctival blanching, pupillary dilation, and Hering effect were recorded at specified time intervals, 1 minute to 1 hour after drop placement. Correlations between patient characteristics and measured outcomes were evaluated using analysis of variance, Pearson coefficient, or chi-square tests. Results: The authors found that 73% of eyes had eyelid elevation with phenylephrine. Of these, 50% reached maximal eyelid elevation by 5 minutes, and 86% by 10 minutes after drop placement, but 14% did not reach maximal MRD-1 until 30 minutes. There is a negative correlation between the maximum MRD-1 and the baseline MRD-1 eyelid height (r = −0.5330, p < 0.01). There is no significant relationship between time to pupillary dilation with either time to max eyelid elevation or max eyelid elevation. No patient characteristic studied affected the likelihood of eyelid response to phenylephrine or presence of Hering effect. Conclusions: Although most ptotic eyelids demonstrate a response to 2.5% phenylephrine within 10 minutes, there is a subset of patients that respond much later. More ptotic eyelids had greater eyelid elevation with phenylephrine. Pupillary dilation and conjunctival blanching are neither predictive of nor temporally associated with eyelid height elevation. The authors did not identify any patient factors (e.g., dermatochalasis, brow ptosis) that can predict the likelihood of response to phenylephrine.
Title: The Phenylephrine Test Revisited
Description:
Purpose: To characterize the phenylephrine test in ptotic patients to help clinicians perform the test more efficiently.
Methods: Adults with involutional ptosis (n = 24, 30 eyes) were assessed with digital photographs for response to topical 2.
5% phenylephrine drop instillation.
Patient characteristics (age, gender, iris color, dermatochalasis, brow ptosis, and baseline marginal reflex distance-1 [MRD-1] height) were recorded.
From the photographs, change in (MRD-1), presence of conjunctival blanching, pupillary dilation, and Hering effect were recorded at specified time intervals, 1 minute to 1 hour after drop placement.
Correlations between patient characteristics and measured outcomes were evaluated using analysis of variance, Pearson coefficient, or chi-square tests.
Results: The authors found that 73% of eyes had eyelid elevation with phenylephrine.
Of these, 50% reached maximal eyelid elevation by 5 minutes, and 86% by 10 minutes after drop placement, but 14% did not reach maximal MRD-1 until 30 minutes.
There is a negative correlation between the maximum MRD-1 and the baseline MRD-1 eyelid height (r = −0.
5330, p < 0.
01).
There is no significant relationship between time to pupillary dilation with either time to max eyelid elevation or max eyelid elevation.
No patient characteristic studied affected the likelihood of eyelid response to phenylephrine or presence of Hering effect.
Conclusions: Although most ptotic eyelids demonstrate a response to 2.
5% phenylephrine within 10 minutes, there is a subset of patients that respond much later.
More ptotic eyelids had greater eyelid elevation with phenylephrine.
Pupillary dilation and conjunctival blanching are neither predictive of nor temporally associated with eyelid height elevation.
The authors did not identify any patient factors (e.
g.
, dermatochalasis, brow ptosis) that can predict the likelihood of response to phenylephrine.

Related Results

The effect of two dose phenylephrin for preventing hypotension during spinal anesthesia for cesarean delivery
The effect of two dose phenylephrin for preventing hypotension during spinal anesthesia for cesarean delivery
Background: Spinal anesthesia-induced hypotension is one of the most complications which can cause many severe maternal and fetal complications. Therefore, the prevention and treat...
Provocative Tests in Diagnosis of Thoracic Outlet Syndrome: A Narrative Review
Provocative Tests in Diagnosis of Thoracic Outlet Syndrome: A Narrative Review
Abstract Thoracic outlet syndrome (TOS) is a group of conditions caused by the compression of the neurovascular bundle within the thoracic outlet. It is classified into three main ...
Effects of Phenylephrine on Ciliary Beat in Human Nasal Respiratory Epithelium: Quantitative Measurement by Video‐Computerized Analysis
Effects of Phenylephrine on Ciliary Beat in Human Nasal Respiratory Epithelium: Quantitative Measurement by Video‐Computerized Analysis
AbstractThe in vitro effects of phenylephrine solution on ciliary beat frequency (CBF) in terms of different concentrations and exposure times were investigated using a video‐compu...
PREVENTION OF OXYTOCIN-INDUCED HYPOTENSION IN CAESAREAN SECTION BY PHENYLEPHRINE: EFFECT OF PRELOAD Dr. Anita Chikara
PREVENTION OF OXYTOCIN-INDUCED HYPOTENSION IN CAESAREAN SECTION BY PHENYLEPHRINE: EFFECT OF PRELOAD Dr. Anita Chikara
Introduction: One of the leading causes of maternal mortality with uterine atony is Postpartum haemorrhage (PPH) and can be reduced by proper use of uterotonic agents like oxytocin...
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
The dose dependency of the alpha‐adrenoceptor antagonist and beta‐ adrenoceptor partial agonist activity of dilevalol and labetalol in man.
1. The alpha‐adrenoceptor antagonist, beta 1‐adrenoceptor antagonist and beta 2‐partial agonist activity of dilevalol, a beta‐adrenoceptor antagonist with vasodilating properties a...

Back to Top